Literature DB >> 28699527

Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery.

Trevor Clancy1, Ruth Dannenfelser2, Olga Troyanskaya2, Karl Johan Malmberg1, Eivind Hovig3, Vessela Kristensen4.   

Abstract

In the microenvironment of a malignancy, tumor cells do not exist in isolation, but rather in a diverse ecosystem consisting not only of heterogeneous tumor-cell clones, but also normal cell types such as fibroblasts, vasculature, and an extensive pool of immune cells at numerous possible stages of activation and differentiation. This results in a complex interplay of diverse cellular signaling systems, where the immune cell component is now established to influence cancer progression and therapeutic response. It is experimentally difficult and laborious to comprehensively and systematically profile these distinct cell types from heterogeneous tumor samples in order to capitalize on potential therapeutic and biomarker discoveries. One emerging solution to address this challenge is to computationally extract cell-type specific information directly from bulk tumors. Such in silico approaches are advantageous because they can capture both the cell-type specific profiles and the tissue systems level of cell-cell interactions. Accurately and comprehensively predicting these patterns in tumors is an important challenge to overcome, not least given the success of immunotherapeutic drug treatment of several human cancers. This is especially challenging for subsets of closely related immune cell phenotypes with relatively small gene expression differences, which have critical functional distinctions. Here, we outline the existing and emerging novel bioinformatics strategies that can be used to profile the tumor immune landscape. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Bioinformatics; Immuno-oncology; Immunotherapy; Systems-immunology; gene expression profiling; immune-cell infiltration

Mesh:

Substances:

Year:  2017        PMID: 28699527     DOI: 10.2174/1381612823666170710154936

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  4 in total

1.  Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab.

Authors:  Shakila Jabeen; Manuela Zucknick; Marianne Nome; Ruth Dannenfelser; Thomas Fleischer; Surendra Kumar; Torben Lüders; Hedda von der Lippe Gythfeldt; Olga Troyanskaya; Jon Amund Kyte; Anne-Lise Børresen-Dale; Bjørn Naume; Xavier Tekpli; Olav Engebraaten; Vessela Kristensen
Journal:  Oncoimmunology       Date:  2018-08-06       Impact factor: 8.110

Review 2.  Tumor microenvironment: barrier or opportunity towards effective cancer therapy.

Authors:  Aadhya Tiwari; Rakesh Trivedi; Shiaw-Yih Lin
Journal:  J Biomed Sci       Date:  2022-10-17       Impact factor: 12.771

3.  An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment.

Authors:  Xavier Tekpli; Tonje Lien; Andreas Hagen Røssevold; Daniel Nebdal; Elin Borgen; Hege Oma Ohnstad; Jon Amund Kyte; Johan Vallon-Christersson; Marie Fongaard; Eldri Undlien Due; Lisa Gregusson Svartdal; My Anh Tu Sveli; Øystein Garred; Arnoldo Frigessi; Kristine Kleivi Sahlberg; Therese Sørlie; Hege G Russnes; Bjørn Naume; Vessela N Kristensen
Journal:  Nat Commun       Date:  2019-12-03       Impact factor: 14.919

4.  In silico analysis of the immune microenvironment in bladder cancer.

Authors:  Ye Zhang; De-Hua Ou; Dong-Wu Zhuang; Ze-Feng Zheng; Ming-En Lin
Journal:  BMC Cancer       Date:  2020-03-30       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.